These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 36222865

  • 1. A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [18F]FDG PET/CT metabolic parameters, inflammatory markers, and clinical variables.
    Zhang L, Xu C, Zhang X, Wang J, Jiang H, Chen J, Zhang H.
    Eur Radiol; 2023 Mar; 33(3):1757-1768. PubMed ID: 36222865
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prognostic impact of the 18F-fluorodeoxyglucose positron-emission tomography/computed tomography metabolic parameters and correlation with hematological inflammatory markers in lung cancer.
    Goksel S, Cengiz A, Ozturk H, Yurekli Y.
    J Cancer Res Ther; 2021 Mar; 17(4):925-930. PubMed ID: 34528543
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nomograms based on SUVmax of 18F-FDG PET/CT and clinical parameters for predicting progression-free and overall survival in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.
    Li H, Shao G, Zhang Y, Chen X, Du C, Wang K, Gao Z.
    Cancer Imaging; 2021 Jan 08; 21(1):9. PubMed ID: 33419476
    [Abstract] [Full Text] [Related]

  • 9. The utility of 68F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.
    Kitajima K, Kawanaka Y, Komoto H, Minami T, Yokoi T, Kuribayashi K, Kijima T, Nakamura A, Hashimoto M, Kondo N, Hasegawa S, Yamakado K.
    Hell J Nucl Med; 2021 Jan 08; 24(3):186-198. PubMed ID: 34901959
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab.
    Eude F, Guisier F, Salaün M, Thiberville L, Pressat-Laffouilhere T, Vera P, Decazes P.
    Ann Nucl Med; 2022 Mar 08; 36(3):224-234. PubMed ID: 35060071
    [Abstract] [Full Text] [Related]

  • 13. Metabolic tumor volume derived from 18F-FDG PET/CT as a prognostic parameter for non-small cell lung cancer (NSCLC) patients.
    Ding C, Mao X, Li N, Huang M, Huang Z, Bao W, Li H, Fan J.
    Hell J Nucl Med; 2022 Mar 08; 25(1):63-70. PubMed ID: 35503557
    [Abstract] [Full Text] [Related]

  • 14. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A, Mohan A, Bhalla AS, Sharma MC, Vishnubhatla S, Das CJ, Pandey AK, Sekhar Bal C, Patel CD, Sharma P, Agarwal KK, Kumar R.
    Clin Nucl Med; 2018 Jan 08; 43(1):e8-e17. PubMed ID: 29112011
    [Abstract] [Full Text] [Related]

  • 15. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F, Wu X, Zhu J, Huang Y, Song X, Jiang L.
    Eur J Nucl Med Mol Imaging; 2021 Sep 08; 48(10):3250-3259. PubMed ID: 33630146
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH, Chiu NT, Su WC, Guo HR, Lee BF.
    Radiology; 2012 Aug 08; 264(2):559-66. PubMed ID: 22692034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.